NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH Portfolio News / By admin October 7, 2019 NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH Read More »
Tenaya Therapeutics Closes $92 Million Series B Financing Portfolio News / By admin October 3, 2019 Tenaya Therapeutics Closes $92 Million Series B Financing Read More »
NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD’s The Liver Meeting Portfolio News / By admin October 3, 2019 NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD’s The Liver Meeting Read More »
Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors Portfolio News / By admin October 1, 2019 Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors Read More »
Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise Portfolio News / By admin September 24, 2019 Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise Read More »
REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor Portfolio News / By admin September 17, 2019 REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor Read More »
Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor Portfolio News / By admin September 4, 2019 Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor Read More »
Kallyope Inc. Appoints Juha Lauren as Chief Business Officer Portfolio News / By admin September 4, 2019 Kallyope Inc. Appoints Juha Lauren as Chief Business Officer Read More »
Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor Portfolio News / By admin September 4, 2019 Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor Read More »
Accent Therapeutics Appoints Shakti Narayan as Chief Executive Officer Portfolio News / By admin September 3, 2019 Accent Therapeutics Appoints Shakti Narayan as Chief Executive Officer Read More »
